What Is Medication-Induced Hearing Loss and Tinnitus?

Medication-induced hearing loss, clinically termed ototoxicity, refers to functional impairment of the inner ear structures—specifically the cochlea and vestibular system—caused by exposure to certain pharmaceutical agents. Tinnitus, the perception of sound in the absence of an external acoustic stimulus, frequently accompanies this hearing loss and may present as ringing, buzzing, hissing, roaring, or clicking sounds. These conditions may be temporary or permanent, unilateral or bilateral, and can manifest within hours or months after drug initiation. The clinical presentation varies widely: some patients experience subtle high-frequency hearing loss detectable only by audiometry, while others develop sudden, debilitating vertigo or constant tinnitus that disrupts sleep and daily function. Understanding the underlying mechanisms, identifying high-risk medications, and implementing effective prevention and management strategies is essential for clinicians across all specialties and for patients who depend on these often life-saving therapies.

Mechanisms of Ototoxicity

Ototoxic drugs damage the delicate sensory hair cells of the cochlea, the spiral ganglion neurons responsible for transmitting auditory signals to the brain, or the stria vascularis that maintains the ionic balance of the endolymph. Aminoglycoside antibiotics, for instance, enter hair cells through mechanotransduction channels and trigger intracellular oxidative stress, leading to apoptosis and irreversible cell death. Platinum-based chemotherapy agents such as cisplatin form DNA adducts and generate reactive oxygen species that overwhelm the cell's antioxidant defenses. Loop diuretics reduce the endocochlear potential by inhibiting the Na-K-2Cl cotransporter in the stria vascularis, which can cause temporary threshold shifts but may become permanent with high cumulative doses or prolonged exposure.

The vestibular system may also be affected, producing symptoms of dizziness, vertigo, oscillopsia, and imbalance. Some drugs produce tinnitus through direct irritation of the auditory nerve or central auditory pathways, even in the absence of measurable hearing loss. Genetic predispositions, such as mutations in mitochondrial DNA (e.g., m.1555A>G), dramatically increase susceptibility to aminoglycoside ototoxicity, sometimes leading to profound hearing loss after a single standard dose. Understanding these mechanisms is critical for developing targeted protective strategies and for recognizing that ototoxicity is not a single phenomenon but a spectrum of injury patterns.

Common Ototoxic Medications

Aminoglycoside Antibiotics

This class includes gentamicin, tobramycin, amikacin, streptomycin, and neomycin. They are potent against Gram-negative bacteria but carry a high risk of cochleotoxicity and vestibulotoxicity. The risk increases with cumulative dose, duration of therapy, and concurrent use of other ototoxic agents. Estimated incidence of hearing loss ranges from 2% to 25% depending on the regimen, monitoring practices, and patient population. Streptomycin is particularly vestibulotoxic, while gentamicin often affects both cochlear and vestibular function. Tobramycin is somewhat less ototoxic than gentamicin but still carries significant risk, especially in patients with cystic fibrosis who receive repeated courses.

Platinum-Based Chemotherapy

Cisplatin and carboplatin are widely used in solid tumors including lung, ovarian, testicular, and head and neck cancers. Cisplatin causes high-frequency hearing loss in 40–80% of adults and even higher rates in children, with some studies reporting rates exceeding 90% in pediatric populations receiving cumulative doses above 400 mg/m². Ototoxicity is dose-related and cumulative, and it is almost always permanent. Carboplatin is slightly less ototoxic when given at standard doses, but high-dose regimens used in stem cell transplantation can lead to substantial hearing impairment. Oxaliplatin, a third-generation platinum agent, rarely causes significant hearing loss, making it a preferred option when audiologic preservation is a priority.

Loop Diuretics

Furosemide, bumetanide, and ethacrynic acid are potent diuretics used in heart failure, renal disease, and hypertension. They produce reversible hearing loss when given intravenously at high doses, but permanent damage can occur if doses are excessive or if other ototoxic drugs are used concurrently. Ethacrynic acid is considered more ototoxic than furosemide and should be avoided in patients with pre-existing hearing loss when alternatives exist. The hearing loss from loop diuretics is typically bilateral and affects all frequencies, though high frequencies are usually affected first.

Salicylates and Nonsteroidal Anti-Inflammatory Drugs

Aspirin at high doses—typically exceeding 6 grams per day for conditions such as rheumatoid arthritis—frequently causes reversible tinnitus and mild hearing loss. The effect is dose-dependent and typically resolves within days of stopping the drug. Other NSAIDs such as ibuprofen, naproxen, and indomethacin have been associated with hearing loss, especially with long-term use or at high doses. The mechanism involves reduced cochlear blood flow and direct hair cell damage. Patients who rely on daily NSAIDs for chronic pain should be counseled about this risk and offered periodic audiologic screening.

Antimalarials

Quinine and its derivatives, including chloroquine and hydroxychloroquine, can produce tinnitus and high-frequency hearing loss that is usually reversible upon discontinuation. Chloroquine has also been linked to irreversible ototoxicity in some cases, especially with prolonged therapy. Given the widespread use of hydroxychloroquine for autoimmune conditions such as lupus and rheumatoid arthritis, clinicians should maintain a high index of suspicion for ototoxicity in this patient population and document baseline audiometry before initiating long-term therapy.

Other Drugs

  • Macrolide antibiotics such as erythromycin and azithromycin can cause transient tinnitus and hearing loss at high intravenous doses, particularly in patients with renal or hepatic impairment.
  • Vancomycin carries ototoxic risk, especially when combined with aminoglycosides or in patients with renal impairment. The risk appears to be dose-dependent and more pronounced with prolonged therapy.
  • Certain antineoplastic agents including vincristine, vinblastine, and bleomycin have been implicated, though less commonly than platinum compounds. These agents typically cause high-frequency hearing loss that may be reversible upon dose reduction.
  • Topical otic preparations containing neomycin, such as Cortisporin, can cause cochlear damage if the eardrum is perforated. Tympanic membrane integrity should always be confirmed before instilling ototoxic ear drops.
  • Phosphodiesterase-5 inhibitors like sildenafil and tadalafil have rare reports of sudden sensorineural hearing loss, prompting an FDA warning. Patients should be advised to discontinue the medication and seek immediate medical evaluation if they experience sudden hearing loss.
  • Loop diuretics as noted above, but also thiazide diuretics at high doses have been associated with mild hearing loss in susceptible individuals.

Risk Factors for Ototoxicity

Dosage and Duration

Higher cumulative doses, prolonged treatment courses, and high peak serum concentrations all increase risk. For aminoglycosides, conventional once-daily dosing reduces ototoxicity compared to multiple daily doses because it allows for a drug-free interval that permits hair cell recovery. For cisplatin, cumulative doses above 300–400 mg/m² carry a steep increase in hearing loss incidence. For loop diuretics, the risk is highest with rapid intravenous administration at high doses.

Renal Impairment

Many ototoxic drugs are eliminated renally. Impaired kidney function leads to prolonged drug exposure, elevating the risk of inner ear damage. Close monitoring of drug levels and adjustment of doses are critical in patients with chronic kidney disease or acute kidney injury. The Cockcroft-Gault equation should be used to estimate creatinine clearance and guide dosing adjustments for renally cleared ototoxins.

Genetic Susceptibility

The mitochondrial 12S rRNA mutation m.1555A>G predisposes individuals to aminoglycoside ototoxicity even at standard doses. This mutation is present in approximately 0.5–2% of the general population but is much more common in certain ethnic groups. Testing for this mutation is recommended before initiating aminoglycoside therapy in patients with a family history of hearing loss or in populations with high carrier rates. Other genetic variants affecting drug transporters and antioxidant enzymes are under investigation and may eventually guide personalized dosing.

Concurrent Noise Exposure

Pre-existing noise-induced hearing loss or exposure to loud noise during ototoxic therapy can synergistically worsen damage. The combination of cisplatin chemotherapy and loud noise exposure, for example, produces greater cochlear damage than either insult alone. Patients on ototoxic medications should be advised to avoid recreational noise, use hearing protection in occupational settings, and limit exposure to personal audio devices at high volumes.

Age and Pre-existing Hearing Loss

Very young children and the elderly are more vulnerable. Neonates have immature renal function and reduced clearance of ototoxic drugs, while their developing auditory systems are particularly sensitive to insult. Older adults may have age-related hearing loss that makes them less tolerant of additional cochlear injury, and presbycusis can mask early ototoxic changes on audiometry.

Drug Interactions

Combining two or more ototoxic agents significantly amplifies risk. The combination of aminoglycosides with loop diuretics, for instance, produces synergistic ototoxicity. Certain medications can also alter drug metabolism or excretion, potentiating ototoxicity. Vancomycin and aminoglycosides should be used together only when absolutely necessary and with careful monitoring of both drug levels and audiologic function.

Prevention Strategies

Pretreatment Assessment

Baseline audiometry should be performed for all patients scheduled to receive known ototoxic drugs, particularly those expected to receive high cumulative doses. For aminoglycosides, genetic testing for the m.1555A>G mutation can identify high-risk individuals. Pre-existing hearing loss and renal function should be documented. A thorough medication history should be taken to identify prior ototoxic exposures and any concurrent ototoxic medications.

Careful Dosing and Monitoring

Use weight-based or area-under-the-curve dosing for carboplatin and cisplatin. Aminoglycoside therapeutic drug monitoring with measurement of trough and peak levels helps maintain efficacy while minimizing toxicity. Once-daily aminoglycoside dosing is preferred over multiple daily doses. For loop diuretics, use the lowest effective dose and avoid rapid intravenous administration. When vancomycin is used, maintain trough levels between 10–20 mcg/mL and consider audiologic monitoring for prolonged courses.

Otoprotective Agents

Several compounds have been studied to prevent ototoxicity without reducing drug efficacy. N-acetylcysteine and sodium thiosulfate have shown promise in animal models and some clinical trials. Sodium thiosulfate is now used in pediatric patients receiving cisplatin for localized hepatoblastoma, where it has been shown to reduce hearing loss without compromising survival. However, concerns about tumor protection when given systemically limit its use in other cancers. D-methionine and aspirin have been investigated but are not yet standard. Ebselen, a glutathione peroxidase mimetic, is in clinical trials for cisplatin ototoxicity. Further research is needed before these agents become widely available.

Alternative Drug Selection

When possible, choose less ototoxic alternatives. For example, fluoroquinolones can replace aminoglycosides in many infections. For hypertension, thiazide diuretics may be used instead of high-dose loop diuretics. In cancer, carboplatin may be substituted for cisplatin when hearing preservation is a priority, though efficacy must be considered on a case-by-case basis. For rheumatoid arthritis, alternative disease-modifying antirheumatic drugs may be considered in patients who develop tinnitus from high-dose salicylates.

Regular Audiologic Surveillance

Patients on ototoxic medications should undergo serial audiometry including baseline, during treatment, and after completion. High-frequency hearing testing up to 12–16 kHz can detect early cochlear changes before they affect speech frequencies. If a significant threshold shift is detected—defined as a 20 dB or greater increase at any frequency—the treating team should consider dose reduction, drug substitution, or discontinuation if clinically feasible. Automated ototoxicity monitoring protocols are available and can streamline surveillance in busy clinical practices.

Management of Ototoxicity

Early Recognition

Patients should be counseled to report any new-onset tinnitus, fullness in the ears, difficulty understanding speech, or dizziness. Healthcare providers should act promptly when hearing changes are noted. A validated questionnaire such as the Tinnitus Handicap Inventory can help quantify the impact of tinnitus on quality of life.

Medical Interventions

If ototoxicity is identified, the first step is to stop or replace the offending agent under medical supervision. Reversible ototoxicity from loop diuretics or high-dose aspirin often resolves within days after discontinuation. Irreversible damage from aminoglycosides or cisplatin requires adaptation and rehabilitation. For sudden sensorineural hearing loss possibly related to medication, corticosteroids may be considered via oral or intratympanic routes, although evidence for ototoxic sudden hearing loss is limited. Tinnitus management may include sound therapy, cognitive behavioral therapy, and in some cases, medications such as tricyclic antidepressants or benzodiazepines, though these are off-label and should be used with caution.

Hearing Rehabilitation

  • Hearing aids – Modern digital hearing aids with directional microphones, noise reduction algorithms, and frequency-specific amplification can improve speech understanding for patients with residual hearing. Open-fit hearing aids are particularly useful for patients with high-frequency hearing loss who retain good low-frequency hearing.
  • Cochlear implants – For severe-to-profound bilateral hearing loss, especially from cisplatin, cochlear implantation provides significant benefit. Many centers now offer implantation early in the course of hearing loss to optimize outcomes. Studies show that cochlear implant recipients who lost hearing from ototoxicity achieve speech perception scores comparable to those with other etiologies.
  • Assistive listening devices – FM systems, amplified telephones, television listening systems, and alerting devices can improve communication in specific environments. These devices are particularly helpful in noisy settings such as restaurants or group meetings.
  • Audiologic rehabilitation – Training in speech reading, communication strategies, and counseling for the emotional impact of hearing loss. Support groups for patients with ototoxic hearing loss can provide valuable peer support.

Vestibular Rehabilitation

Patients with balance problems from vestibulotoxic drugs may benefit from vestibular physical therapy. Exercises that promote central compensation, such as gaze stabilization and habituation exercises, can reduce dizziness and fall risk. The Cawthorne-Cooksey exercises are a well-established protocol for vestibular rehabilitation. Patients with bilateral vestibular loss may require specialized therapy focused on balance retraining and fall prevention.

Prognosis and Long-Term Outcomes

The prognosis depends on the drug, dose, duration, and patient factors. Reversible ototoxins such as loop diuretics and salicylates generally have excellent recovery if caught early. Aminoglycoside-induced hearing loss is often permanent, though some recovery in the first few weeks is possible in a minority of patients. Cisplatin ototoxicity is almost always permanent and may continue to worsen after the end of treatment due to delayed cochlear injury. Children treated with cisplatin are at high risk for lifelong hearing loss, which impacts language development, academic performance, and social functioning. Early intervention with hearing aids or cochlear implants can mitigate these effects.

Regular follow-up with audiology is recommended for several years after ototoxic exposure, especially in pediatric cancer survivors. Tinnitus may persist even when hearing loss is stable; tinnitus management through cognitive behavioral therapy and sound therapy can improve quality of life. Patients with permanent hearing loss should be evaluated for disability benefits and workplace accommodations as needed.

Emerging Research and Future Directions

Ongoing research aims to identify biomarkers of ototoxicity that could predict damage before it becomes clinically apparent. Genetic screening for susceptibility variants may become routine as the cost of sequencing decreases. Otoprotective drugs such as ebselen, a glutathione peroxidase mimetic, and STAT3 inhibitors are in preclinical and early clinical stages. Additionally, gene therapy to promote hair cell regeneration is being explored in animal models using AAV vectors to deliver transcription factors such as Atoh1, though human applications remain years away.

Clinical trials continue to evaluate the efficacy of sodium thiosulfate in different tumor types, as well as penicillamine and vitamin E for aminoglycoside ototoxicity. The American Academy of Otolaryngology–Head and Neck Surgery and the American Speech-Language-Hearing Association have published clinical practice guidelines on ototoxicity monitoring that are updated regularly. Investigational agents such as KENA-004 and ORC-13661 are being developed specifically for cisplatin ototoxicity prevention. The National Institute on Deafness and Other Communication Disorders continues to fund research on otoprotection and hearing restoration.

Conclusion

Medication-induced hearing loss and tinnitus are significant, often preventable causes of hearing disability that affect patients across the lifespan. Awareness among prescribers and patients is the first line of defense. Through baseline audiology, careful dose management, pharmacovigilance, and routine monitoring, the incidence and severity of ototoxicity can be reduced. For those who experience permanent damage, modern hearing rehabilitation offers substantial improvement in communication and quality of life. As research continues, better predictive tools and protective therapies will further minimize the impact of these essential drugs on auditory health. Clinicians should remain vigilant, counsel patients proactively, and collaborate with audiologists to ensure optimal outcomes.

Additional Resources